CYP2C19 and cancer: Likewise, the population PK investigation of the recently approved anti-cancer drug belzutifan revealed that the dual UGT2B17 and CYP2C19 poor metabolizers are expected to show a 3.2-fold AUC [19], which could lead to adverse events.